Skip to main content
The Globe and Mail
Get full access to globeandmail.com
Support quality journalism
Just $1.99 per week for the first 24weeks
Just $1.99 per week for the first 24weeks
The Globe and Mail
Support quality journalism
Get full access to globeandmail.com
Globe and Mail website displayed on various devices
Just$1.99
per week
for the first 24weeks

var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){console.log("scroll");var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))}pencilInit(".js-sub-pencil",!1);

U.S. venture capital firm Versant Partners, which specializes in life sciences, is adding to its Montreal division after launching a Vancouver office earlier this year.

iStockphoto

Venture capital firm Versant Ventures is expanding its investment network in Canada.

The California-based investment company that specializes in life sciences – from medical devices to biopharmaceuticals – said Monday it is planning to add a Montreal-based investment division aimed at starting new companies from scratch.

This follows other recent efforts by the firm to seek out investment opportunities in the country. This year Versant launched a Vancouver office, and it recently formed a partnership with Bayer HealthCare to invest in a company called Inception 4, which is focused on the treatment of retinal eye disease. Versant invested $10-million.

Story continues below advertisement

"There's a lot of good discovery research in Canada," said Jerel Davis, a principal with Versant Ventures who recently moved to Vancouver from San Francisco.

Biotech stocks have soared this year, benefiting from the heat radiating off of the broader health care and technology sectors. Heavyweights Celgene Corp. and Gilead Sciences are both up well over 100 per cent so far in 2013.

Venture capital for life sciences, biotechnology and related fields is hard to come by in Canada. Growth of companies based on science can be stunted without necessary funding because of the high costs of research. While some groups have increased their investments with the favourable markets, funding is still in demand. At the same time, large companies are relying on small companies for new ideas – Versant says that 40 to 50 per cent of new drugs now have their roots in small companies or academic research.

To reduce some of the risk Versant uses a business investment model that prenegotiates a deal for the startup, should it be successful. The established players such as Celgene and Bayer provide some research funding, and gain the option to acquire the business later. This gives Versant an exit strategy in its three– to four-year time horizon.

The process involves looking for promising research, finding corporate partners with specific needs, and then matching them up.

Versant is partnering with major international companies on what it sees as neglected investment opportunities in Canadian science.

"There are very few investors looking at the discoveries in B.C., Ontario and Quebec and trying to figure out how to build companies, and that's attractive to us," Mr. Davis said. "It's in contrast to other geographies in the U.S. where there's lots more investment."

Story continues below advertisement

In November it founded Blueline Bioscience, a Toronto-based "biotechnology incubator" that will work with aforementioned Celgene to help startups specializing in areas such as oncology get off the ground. The group works out of the MaRS Discovery District of Toronto.

Versant is already an established investment group in the U.S., where it has $1.6-billion under management, and Western Europe. It has launched more than 120 companies.

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies